COMPANY PROFILE

Contraria Biotech

Develops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics

Siena, ItalyFounded 2017Biotech & Life Sciences

Valuation $25–50M Last recorded · 2020

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Contraria Biotech

Achilles Vaccines operates in the biopharmaceutical sector, focusing on the early-stage development of vaccines and immunotherapeutics. The company leverages a versatile technology platform that utilizes bacteria to produce self-adjuvanting vesicles capable of delivering antigenic molecules. Achilles Vaccines serves clients in the healthcare and pharmaceutical industries, addressing critical needs such as malaria, COVID-19, and bacterial infections. The company employs advanced laboratory and digital technologies, including the NGVR method, to rapidly identify effective vaccine targets. Its business model revolves around research and development, supported by significant seed financing and partnerships, such as the EU Malaria Fund. Revenue is generated through the development and commercialization of biopharmaceutical products, including vaccines and immunotherapeutics.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Siena, Italy
Employees: 11
Open positions: None listed
Dealroom signal: 33.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Jun 2020	$12M	$48M	European Investment Bank · Bill & Melinda Gates Foundation · Toscana Life Sciences · Fondazione Monte dei Paschi di Siena	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Contraria Biotech website traffic

Latest recorded traffic for Contraria Biotech is 220 monthly website visits, down 18.5% over the last three months. Contraria Biotech's team grew 0% over the past year.

Latest monthly visits220 3-month web change-18.5% 1-year team growth0%

Monthly website visitsJun 2020–Feb 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational	5,211	$1.7B	$7.4B
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
CICHA Vaccine InstituteTea vaccine research is a state-of-the-art biotech company developing vaccines and immunotherapys	South Korea	Operational
ATAlterome TherapeuticsA biopharmaceutical company developing alteration-specific targeted therapies	San Diego, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
ESEsperovaxEsperovax is working to create vaccines for some of the world’s most deadly diseases	Plymouth Township, United States	Operational
MBMicron BiomedicalBiopharmaceutical company on a rapid path to bring to market drugs and vaccines	Atlanta, United States	Operational